Director Kiai Parsa Buys $842,699 of Medifast Stock
MED sits 25% above its 52-week low of $9.22 on light trading volume (0.1× avg).
Summary
Director Kiai Parsa bought $842,699 worth of Medifast stock in four open-market purchases on August 19–20, 2026, increasing his indirect holdings to 661,306 shares.
Key Events · Ownership and Investor Activity · MED
-
Director Buys $842,699 in Stock
Kiai Parsa purchased 72,487 shares across four transactions on August 19–20, 2026, at prices ranging $11.46–$11.80.
-
Post-Transaction Holdings
Parsa's indirect holdings now total 661,306 shares, held through Steamboat Capital Partners funds.
-
Context: Recent Operational Headwinds
The purchase follows Medifast's Q2 2026 revenue decline of 27.6% and a net loss of $3.1 million, as well as recent executive departures.
-
Insider Conviction Signal
As a director, Parsa's open-market purchase of this size suggests confidence in the company's long-term value despite near-term challenges.
Analysis · MED · Manufacturing
Director Kiai Parsa purchased 72,487 shares for $842,699 across four transactions on August 19–20, 2026, at prices between $11.46 and $11.80. The purchase represents a meaningful personal investment by a board member, especially against the backdrop of Medifast's recent revenue decline and executive turnover. While Parsa is not a C-suite officer, the size of the buy—roughly 0.65% of the company's market cap—signals conviction in the company's turnaround prospects.
At the time of this filing, MED was trading at $11.56 on NYSE in the Manufacturing sector, with a market capitalization of approximately $129.2M. The 52-week trading range was $9.22 to $14.67. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.